Dallah profit jumps 30% to SAR 155.6M in Q1 2025

11/05/2025 Argaam Exclusive

View other reports

Dallah Healthcare Co.’s Q1 2025 net profit jumped 30% to SAR 155.6 million from SAR 119.3 million in Q1 2024.

Current Quarter Comparison (M)

Compared With The

Item	Q1 2024	Q1 2025	Change‬
Revenues	784.06	832.75	6.2 %
Gross Income	293.36	297.61	1.4 %
Operating Income	143.22	119.94	(16.3 %)
Net Income	119.30	155.56	30.4 %
Average Shares	97.68	101.57	4.0 %
Earnings Per Share before unusual items (Riyal)	1.22	1.03	(16.1 %)
EPS (Riyal)	1.22	1.53	25.4 %

Item	Q4 2024	Q1 2025	Change‬
Revenues	808.76	832.75	3.0 %
Gross Income	292.76	297.61	1.7 %
Operating Income	107.98	119.94	11.1 %
Net Income	113.90	155.56	36.6 %
Average Shares	97.68	101.57	4.0 %
Earnings Per Share before unusual items (Riyal)	1.17	1.03	(12.1 %)
EPS (Riyal)	1.17	1.53	31.3 %

The profit increase is driven by a 6.2% year-on-year (YoY) rise in revenue to SAR 833 million. This increase was realized despite the current quarter being impacted by the seasonality associated with the month of Ramadan and Eid Al-Fitr. This was driven by increased operational capacity as a result of the group's strategic expansions, both in existing and acquired medical facilities, which contributed to the continued growth in the number of patients for the group's hospitals.

The acquisition of Al-Salam Medical Services Co. (owner of Dallah Al-Khobar Hospital), and Al-Ahsa Medical Services Co. (owner of Dallah Al-Ahsa Hospital), had a positive impact on revenue growth.

In addition, the company's 33.33% stake in a real estate fund through an in-kind contribution of lands resulted in non-recurring gains of SAR 51 million. The fund raised SAR 613 million in capital and aims to develop a mixed-use project comprising commercial, office, hospitality, and healthcare space in Al Nakheel district on King Fahd Road in Riyadh.

On a sequential basis, the net earnings grew by 36.6% from SAR 113.9 million in Q4 2024.

Shareholders’ equity, excluding minority interest, reached SAR 4.06 billion as of March 31, 2025, up from SAR 3.32 billion a year earlier.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2016	285.03	18.6 %	132.53	29.8 %	61.90	56.1 %
Q2 2016	288.35	17.6 %	129.78	28.6 %	59.34	66.2 %
Q3 2016	273.17	22.0 %	122.38	39.2 %	51.80	96.4 %
Q4 2016	316.24	14.4 %	151.01	29.3 %	57.96	1.7 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
Q1 2017	302.75	6.2 %	143.60	8.4 %	85.82	38.6 %
Q2 2017	288.20	0.0 %	130.48	0.5 %	70.86	19.4 %
Q3 2017	295.25	8.1 %	136.77	11.8 %	76.36	47.4 %
Q4 2017	325.87	3.0 %	148.23	(1.8 %)	74.95	29.3 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
Q1 2018	308.59	1.9 %	131.73	(8.3 %)	59.44	(30.7 %)
Q2 2018	273.13	(5.2 %)	92.38	(29.2 %)	19.67	(72.2 %)
Q3 2018	280.94	(4.8 %)	101.37	(25.9 %)	33.44	(56.2 %)
Q4 2018	318.28	(2.3 %)	110.86	(25.2 %)	33.04	(55.9 %)
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
Q1 2019	321.15	4.1 %	120.26	(8.7 %)	41.24	(30.6 %)
Q2 2019	286.00	4.7 %	92.46	0.1 %	18.06	(8.2 %)
Q3 2019	301.34	7.3 %	107.78	6.3 %	30.99	(7.3 %)
Q4 2019	343.60	8.0 %	127.34	14.9 %	64.09	94.0 %
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
Q1 2020	314.61	(2.0 %)	105.76	(12.1 %)	26.42	(35.9 %)
Q2 2020	247.56	(13.4 %)	67.77	(26.7 %)	7.97	(55.9 %)
Q3 2020	350.79	16.4 %	132.62	23.0 %	50.51	63.0 %
Q4 2020	405.30	18.0 %	143.57	12.7 %	40.26	(37.2 %)
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
Q1 2021	494.67	57.2 %	176.82	67.2 %	72.91	176.0 %
Q2 2021	490.83	98.3 %	168.17	148.1 %	68.57	760.1 %
Q3 2021	544.12	55.1 %	192.46	45.1 %	69.95	38.5 %
Q4 2021	575.57	42.0 %	222.91	55.3 %	116.48	189.4 %
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
Q1 2022	609.40	23.2 %	231.69	31.0 %	109.93	50.8 %
Q2 2022	583.82	18.9 %	212.13	26.1 %	96.68	41.0 %
Q3 2022	600.89	10.4 %	211.47	9.9 %	84.19	20.4 %
Q4 2022	693.88	20.6 %	239.81	7.6 %	101.69	(12.7 %)
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
Q1 2023	716.64	17.6 %	266.79	15.1 %	132.49	20.5 %
Q2 2023	670.42	14.8 %	235.08	10.8 %	87.85	(9.1 %)
Q3 2023	749.83	24.8 %	280.86	32.8 %	130.97	55.6 %
Q4 2023	806.01	16.2 %	295.94	23.4 %	126.50	24.4 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %
Q1 2024	784.06	9.4 %	293.36	10.0 %	143.22	8.1 %
Q2 2024	765.18	14.1 %	297.73	26.7 %	135.70	54.5 %
Q3 2024	847.73	13.1 %	322.99	15.0 %	155.15	18.5 %
Q4 2024	808.76	0.3 %	292.76	(1.1 %)	107.98	(14.6 %)
2024	3,205.73	8.9 %	1,206.84	11.9 %	542.06	14.9 %
Q1 2025	832.75	6.2 %	297.61	1.4 %	119.94	(16.3 %)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %
2024	3,205.73	8.9 %	1,206.84	11.9 %	542.06	14.9 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2016	58.07	21.4 %	0.65	(2.02)	60.09	0.67
Q2 2016	54.14	51.0 %	0.60	(3.07)	57.21	0.64
Q3 2016	60.80	127.0 %	0.68	9.42	51.39	0.57
Q4 2016	51.71	(5.3 %)	0.57	(6.00)	57.71	0.64
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
Q1 2017	85.05	46.5 %	0.94	-	85.05	0.94
Q2 2017	69.99	29.3 %	0.78	-	69.99	0.78
Q3 2017	76.82	26.3 %	0.85	-	76.82	0.85
Q4 2017	63.12	22.1 %	0.70	(11.69)	74.81	0.83
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
Q1 2018	58.09	(31.7 %)	0.65	-	58.09	0.65
Q2 2018	18.73	(73.2 %)	0.21	-	18.73	0.21
Q3 2018	32.48	(57.7 %)	0.36	-	32.48	0.36
Q4 2018	32.47	(48.6 %)	0.36	-	32.47	0.36
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
Q1 2019	35.17	(39.5 %)	0.39	-	35.17	0.39
Q2 2019	15.35	(18.1 %)	0.17	-	15.35	0.17
Q3 2019	26.62	(18.1 %)	0.30	-	26.62	0.30
Q4 2019	69.79	115.0 %	0.78	13.39	56.41	0.63
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
Q1 2020	19.24	(45.3 %)	0.21	-	19.24	0.21
Q2 2020	6.99	(54.4 %)	0.08	-	6.99	0.08
Q3 2020	53.78	102.1 %	0.60	16.36	37.42	0.42
Q4 2020	17.11	(75.5 %)	0.19	-	17.11	0.19
2020	97.13	(33.9 %)	1.08	16.36	80.76	0.90
Q1 2021	52.61	173.4 %	0.58	-	52.61	0.58
Q2 2021	47.54	579.9 %	0.53	-	47.54	0.53
Q3 2021	49.85	(7.3 %)	0.55	-	49.85	0.55
Q4 2021	108.60	534.6 %	1.21	10.35	98.25	1.09
2021	258.60	166.3 %	2.87	10.35	248.26	2.76
Q1 2022	82.63	57.1 %	0.92	-	82.63	0.92
Q2 2022	69.52	46.2 %	0.77	-	69.52	0.77
Q3 2022	43.87	(12.0 %)	0.49	-	43.87	0.49
Q4 2022	78.44	(27.8 %)	0.87	-	78.44	0.87
2022	274.46	6.1 %	3.05	-	274.46	3.05
Q1 2023	94.66	14.6 %	0.97	-	94.66	0.97
Q2 2023	53.01	(23.8 %)	0.54	-	53.01	0.54
Q3 2023	98.87	125.4 %	1.01	-	98.87	1.01
Q4 2023	113.65	44.9 %	1.16	-	113.65	1.16
2023	360.12	31.2 %	3.69	-	360.12	3.69
Q1 2024	119.30	26.0 %	1.22	-	119.30	1.22
Q2 2024	111.84	111.0 %	1.14	-	111.84	1.14
Q3 2024	126.15	27.6 %	1.29	-	126.15	1.29
Q4 2024	113.90	0.2 %	1.17	-	113.90	1.17
2024	471.20	30.8 %	4.82	-	471.20	4.82
Q1 2025	155.56	30.4 %	1.53	51.44	104.13	1.03

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
2020	97.13	(33.9 %)	1.08	16.36	80.76	0.90
2021	258.60	166.3 %	2.87	10.35	248.26	2.76
2022	274.46	6.1 %	3.05	-	274.46	3.05
2023	360.12	31.2 %	3.69	-	360.12	3.69
2024	471.20	30.8 %	4.82	-	471.20	4.82

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	42.51 %	23.29 %	17.20 %
Q2 2016	43.49 %	24.24 %	18.50 %
Q3 2016	44.66 %	25.57 %	19.88 %
Q4 2016	46.07 %	24.94 %	19.47 %
2016	46.07 %	24.94 %	19.47 %
Q1 2017	46.32 %	26.38 %	21.29 %
Q2 2017	46.38 %	27.68 %	22.38 %
Q3 2017	46.73 %	29.19 %	24.08 %
Q4 2017	46.13 %	30.34 %	25.30 %
2017	46.13 %	30.34 %	25.30 %
Q1 2018	44.93 %	28.26 %	22.97 %
Q2 2018	42.33 %	24.50 %	18.99 %
Q3 2018	39.86 %	21.41 %	15.49 %
Q4 2018	36.95 %	18.60 %	12.00 %
2018	36.95 %	18.60 %	12.00 %
Q1 2019	35.60 %	17.66 %	9.96 %
Q2 2019	35.23 %	17.77 %	9.57 %
Q3 2019	35.16 %	17.58 %	8.93 %
Q4 2019	35.77 %	19.73 %	10.66 %
2019	35.77 %	19.73 %	10.66 %
Q1 2020	34.79 %	18.58 %	9.44 %
Q2 2020	33.85 %	18.13 %	9.05 %
Q3 2020	34.50 %	19.13 %	9.55 %
Q4 2020	34.12 %	16.71 %	6.13 %
2020	34.12 %	16.71 %	6.13 %
Q1 2021	34.76 %	18.09 %	7.62 %
Q2 2021	35.67 %	19.32 %	8.88 %
Q3 2021	35.20 %	18.83 %	8.64 %
Q4 2021	36.12 %	21.04 %	11.79 %
2021	36.12 %	21.04 %	11.79 %
Q1 2022	36.72 %	21.66 %	12.54 %
Q2 2022	37.15 %	22.13 %	12.98 %
Q3 2022	37.06 %	22.17 %	12.42 %
Q4 2022	35.98 %	20.37 %	11.03 %
2022	35.98 %	20.37 %	11.03 %
Q1 2023	35.84 %	20.47 %	11.04 %
Q2 2023	35.54 %	19.47 %	10.07 %
Q3 2023	36.12 %	20.16 %	11.48 %
Q4 2023	36.65 %	20.50 %	12.24 %
2023	36.65 %	20.29 %	12.24 %
Q1 2024	36.72 %	20.57 %	12.78 %
Q2 2024	37.61 %	21.64 %	14.29 %
Q3 2024	37.78 %	21.79 %	14.70 %
Q4 2024	37.65 %	21.29 %	14.70 %
2024	37.65 %	21.29 %	14.70 %
Q1 2025	37.21 %	20.55 %	14.01 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	41.32 %	22.03 %	15.35 %
2016	46.07 %	24.94 %	19.47 %
2017	46.13 %	30.34 %	25.30 %
2018	36.95 %	18.60 %	12.00 %
2019	35.77 %	19.73 %	10.66 %
2020	34.12 %	16.71 %	6.13 %
2021	36.12 %	21.04 %	11.79 %
2022	35.98 %	20.37 %	11.03 %
2023	36.65 %	20.29 %	12.24 %
2024	37.65 %	21.29 %	14.70 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	46.50 %	26.86 %	21.08 %
Q2 2016	45.01 %	25.49 %	19.84 %
Q3 2016	44.80 %	24.50 %	18.81 %
Q4 2016	47.75 %	23.08 %	18.25 %
Q1 2017	47.43 %	32.36 %	28.09 %
Q2 2017	45.27 %	30.84 %	24.28 %
Q3 2017	46.32 %	30.89 %	26.02 %
Q4 2017	45.49 %	27.52 %	22.96 %
Q1 2018	42.69 %	24.11 %	18.82 %
Q2 2018	33.82 %	14.42 %	6.86 %
Q3 2018	36.08 %	18.15 %	11.56 %
Q4 2018	34.83 %	17.24 %	10.20 %
Q1 2019	37.45 %	20.42 %	10.95 %
Q2 2019	32.33 %	15.01 %	5.37 %
Q3 2019	35.77 %	17.35 %	8.83 %
Q4 2019	37.06 %	25.11 %	16.42 %
Q1 2020	33.62 %	15.88 %	6.12 %
Q2 2020	27.38 %	12.22 %	2.82 %
Q3 2020	37.81 %	21.04 %	10.67 %
Q4 2020	35.42 %	16.33 %	4.22 %
Q1 2021	35.75 %	20.37 %	10.64 %
Q2 2021	34.26 %	19.51 %	9.69 %
Q3 2021	35.37 %	18.67 %	9.16 %
Q4 2021	38.73 %	25.18 %	17.07 %
Q1 2022	38.02 %	22.74 %	13.56 %
Q2 2022	36.34 %	21.69 %	11.91 %
Q3 2022	35.19 %	19.15 %	7.30 %
Q4 2022	34.56 %	18.22 %	11.30 %
Q1 2023	37.23 %	22.77 %	13.21 %
Q2 2023	35.06 %	17.54 %	7.91 %
Q3 2023	37.46 %	21.82 %	13.19 %
Q4 2023	36.72 %	19.74 %	14.10 %
Q1 2024	37.42 %	22.82 %	15.22 %
Q2 2024	38.91 %	22.24 %	14.62 %
Q3 2024	38.10 %	22.38 %	14.88 %
Q4 2024	36.20 %	17.77 %	14.08 %
Q1 2025	35.74 %	19.81 %	12.50 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2016	90.00	1.95	1.97	16.15
Q2 2016	90.00	2.15	2.21	15.76
Q3 2016	90.00	2.53	2.48	16.26
Q4 2016	90.00	2.50	2.52	16.85
Q1 2017	90.00	2.80	2.79	17.78
Q2 2017	90.00	2.97	2.93	17.24
Q3 2017	90.00	3.15	3.22	18.05
Q4 2017	90.00	3.28	3.41	18.80
Q1 2018	90.00	2.98	3.11	19.41
Q2 2018	90.00	2.41	2.54	17.98
Q3 2018	90.00	1.92	2.05	18.34
Q4 2018	90.00	1.58	1.58	17.79
Q1 2019	90.00	1.32	1.32	18.07
Q2 2019	90.00	1.28	1.28	16.24
Q3 2019	90.00	1.22	1.22	16.54
Q4 2019	90.00	1.63	1.48	16.91
Q1 2020	90.00	1.46	1.31	16.57
Q2 2020	90.00	1.36	1.21	16.65
Q3 2020	90.00	1.66	1.33	17.25
Q4 2020	90.00	1.08	0.90	19.94
Q1 2021	90.00	1.45	1.27	19.89
Q2 2021	90.00	1.90	1.72	20.42
Q3 2021	90.00	1.86	1.86	20.86
Q4 2021	90.00	2.87	2.76	20.74
Q1 2022	90.00	3.21	3.09	21.70
Q2 2022	90.00	3.45	3.34	22.47
Q3 2022	90.00	3.38	3.27	21.96
Q4 2022	90.00	3.05	3.05	22.11
Q1 2023	97.68	2.93	2.93	32.03
Q2 2023	97.68	2.76	2.76	32.07
Q3 2023	97.68	3.33	3.33	32.64
Q4 2023	97.68	3.69	3.69	32.79
Q1 2024	97.68	3.94	3.94	34.02
Q2 2024	97.68	4.54	4.54	34.51
Q3 2024	97.68	4.82	4.82	34.96
Q4 2024	97.68	4.82	4.82	35.51
Q1 2025	101.57	5.00	4.49	39.98

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	90.00	1.83	1.68	15.48
2016	90.00	2.50	2.52	16.85
2017	90.00	3.28	3.41	18.80
2018	90.00	1.58	1.58	17.79
2019	90.00	1.63	1.48	16.91
2020	90.00	1.08	0.90	19.94
2021	90.00	2.87	2.76	20.74
2022	90.00	3.05	3.05	22.11
2023	97.68	3.69	3.69	32.79
2024	97.68	4.82	4.82	35.51

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2016	28.55	28.22	3.44
Q2 2016	29.68	28.92	4.05
Q3 2016	22.14	22.57	3.44
Q4 2016	28.13	27.92	4.17
Q1 2017	26.99	27.02	4.24
Q2 2017	27.88	28.24	4.81
Q3 2017	25.62	25.09	4.47
Q4 2017	22.81	21.94	3.98
Q1 2018	25.79	24.71	3.96
Q2 2018	29.56	28.04	3.96
Q3 2018	23.83	22.32	2.49
Q4 2018	26.40	26.40	2.34
Q1 2019	34.12	34.12	2.49
Q2 2019	36.29	36.29	2.87
Q3 2019	37.54	37.54	2.76
Q4 2019	26.96	29.67	2.60
Q1 2020	29.56	32.93	2.60
Q2 2020	32.37	36.33	2.65
Q3 2020	32.00	39.93	3.09
Q4 2020	50.46	60.68	2.73
Q1 2021	41.02	46.90	2.99
Q2 2021	47.15	52.14	4.39
Q3 2021	43.03	43.03	3.83
Q4 2021	29.50	30.73	4.09
Q1 2022	35.69	37.01	5.27
Q2 2022	36.23	37.48	5.56
Q3 2022	52.68	54.54	8.12
Q4 2022	54.77	54.77	7.55
Q1 2023	54.60	54.60	5.00
Q2 2023	63.13	63.13	5.44
Q3 2023	44.57	44.57	4.54
Q4 2023	48.45	48.45	5.45
Q1 2024	44.18	44.18	5.12
Q2 2024	35.44	35.44	4.66
Q3 2024	34.72	34.72	4.79
Q4 2024	32.21	32.21	4.39
Q1 2025	25.34	28.20	3.17

Period	P/E	Recurring P/E	Price/book
2015	28.34	30.92	3.36
2016	28.13	27.92	4.17
2017	22.81	21.94	3.98
2018	26.40	26.40	2.34
2019	26.96	29.67	2.60
2020	50.46	60.68	2.73
2021	29.50	30.73	4.09
2022	54.77	54.77	7.55
2023	48.46	48.46	5.45
2024	31.34	31.34	4.39

Business Segments (Million)

Compared With The

Period	Medical Services	Medicine and Pharmaceutical Products
Q1 2016	276.15	8.88
Q2 2016	277.42	10.93
Q3 2016	265.04	8.13
Q4 2016	307.51	8.73
Q1 2017	239.94	62.81
Q2 2017	229.31	58.90
Q3 2017	235.08	60.17
Q4 2017	241.44	84.43
Q1 2018	236.76	71.84
Q2 2018	205.73	67.39
Q3 2018	218.43	62.50
Q4 2018	228.74	89.55
Q1 2019	239.22	81.93
Q2 2019	210.95	75.06
Q3 2019	232.55	68.79
Q4 2019	259.40	84.20
Q1 2020	227.83	86.77
Q2 2020	166.96	80.60
Q3 2020	260.50	90.30
Q4 2020	309.74	95.55
Q1 2021	378.70	115.97
Q2 2021	374.54	116.29
Q3 2021	412.23	131.88
Q4 2021	472.23	103.34
Q1 2022	470.53	138.87
Q2 2022	475.30	108.52
Q3 2022	438.86	162.03
Q4 2022	547.10	146.77
Q1 2023	530.59	186.05
Q2 2023	513.01	157.40
Q3 2023	518.40	231.43
Q4 2023	597.28	208.74
Q1 2024	574.66	209.40
Q2 2024	550.68	214.50
Q3 2024	628.19	219.55
Q4 2024	467.66	341.10
Q1 2025	581.02	251.74

Period	Medical Services	Medicine and Pharmaceutical Products
2015	925.20	60.24
2016	1,126.12	36.67
2017	945.78	266.30
2018	889.66	291.28
2019	942.12	309.97
2020	965.03	353.22
2021	1,637.71	467.47
2022	1,931.79	556.20
2023	2,159.27	783.63
2024	2,221.19	984.55

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change	Profit Before Unusual Items	Change
Average	120.93	155.56		104.13

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)	Profit Before Unusual Items
SNB Capital	133.00	155.56	104.13
Goldman Sachs	122.91	155.56	104.13
Al Rajhi Capital	115.00	155.56	104.13
AlJazira Capital	112.80	155.56	104.13

Financial Ratios

	Current
Market Cap (M Riyal)	12,696.89
Enterprise Value (EV) (M Riyal)	15,972.86
Shares Outstanding ((M))	101.58
EPS ( Riyal) (TTM)	5.12
Book Value (BV) ( Riyal)	40.71
Par Value ( Riyal)	10.00
Recurring P/E	27.85
P/E (TTM)	24.42
Price/book	3.07
Return on Average Assets (%) (TTM)	6.9
Return on Average Equity (%) (TTM)	13.9
EV/adj EBITDA	22.55
EV/Revenues	4.50

Dallah Healthcare Co. (DALLAH HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Dallah profit jumps 30% to SAR 155.6M in Q1 2025

View other reports

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2025 Q1

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Dallah profit jumps 30% to SAR 155.6M in Q1 2025

View other reports

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q1 2025

Revenue by Business Segment (Latest) 2025 Q1

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)